Ofatumumab Versus Intravenous Ocrelizumab after Sphingosine-1-Phosphate Receptor Modulators in Patients with Relapsing-Remitting Multiple Sclerosis: A Real-World Inverse Probability of Treatment Weighting Multicenter Study.
Abbadessa G, Marastoni D, Bile F, Signoriello E, Zanghì A, Cellerino M, Cerqua R, Evangelista L, Tomassini V, Sensi S, Romano G, Risi M, Lagonigro E, Mazzone A, Gelibter S, Rispoli M, Vercellino M, Schirò G, Ragonese P, Sartori A, Malagù S, Ganino C, Mancinelli L, Lugaresi A, Lus G, Rosso F, Comar M, Merlino G, Valente M, Montepietra S, Marti A, Piscaglia MG, Surcinelli A, Tsantes E, Curti E, Fiore A, Ferraro D, Fantozzi R, Lavorgna L, D'Amico E, Gallo A, Cavalla P, Calabrese M, Inglese M, Bonavita S, Foschi M.
Abbadessa G, et al. Among authors: mancinelli l.
CNS Drugs. 2026 Jan 28. doi: 10.1007/s40263-025-01267-4. Online ahead of print.
CNS Drugs. 2026.
PMID: 41604125